Visual and Morphologic Outcomes of Intravitreal Bevacizumab for Diabetic Macular Edema Based on OCT Patterns: A Retrospective Study
Article Sidebar
Main Article Content
Abstract
Purpose: To evaluate the visual and morphologic outcomes of intravitreal bevacizumab (IVB) injection in eyes with diabetic macular edema (DME) based on the morphologic patterns on the optical coherence tomography (OCT) at 6 months. Method: A retrospective comparative study of 64 eyes of type 2 diabetics with DME classified according to OCT patterns: diffuse retinal thickening (DRT), cystoid macular edema (CME), and serous retinal detachment (SRD) was performed. Every patient received 3 monthly IVB injections and as needed thereafter. The primary outcome was the changes in the best corrected visual acuity (BCVA) and central foveal thickness (CFT) measured by optical coherence tomography for duration of 6 months after the first injection. Results: The 64 eyes were classified as 24 (37.5%) of the DRT type, 21 (32.8%) of the CME type, and 19 (29.7%) of the SRD type. Before the injection, there were no significant differences in BCVA and CFT among different DME types (P = 0.875, 0.294 respectively). At 6 months after treatment, there were significant improvements of BCVA and CFT from baseline in all 3 DME types (P < 0.001) without significant difference among each OCT pattern (P = 0.220 for BCVA, P = 0.635 for CFT). The DRT type seemed to have the slightly more preferable results than the other types. Conclusion: Vision gain and anatomic improvement were achieved and maintained in all three DME types for at 6 months after intravitreal bevacizumab injections.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema, report #1. Arch Ophthalmol 1985; 103: 1796-806.
Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmol 1984; 91: 1-9.
Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012; 366: 1227-39.
Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010; 26: 1587-97.
Ma JX, Zhang SX, Wang JJ. Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications. Curr Diabetes Rev 2005; 1: 183-96.
Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999; 127: 688-93.
Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthamol 1999; 14: 223-32.
Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 1997; 29: 354-62.
Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maima M, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Ophthalmol 2007; 114: 743-50.
Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal Bevacizumab (Avastin) therapy for persistant diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
Masahiko S, Kanako Y, Masayuki Y, Toru N. Visual outcome after intravitreal Bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema. Retina 2013; 33: 740-7.
Wu PC, Lai CH, Chen CL, Kuo CN. Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevazicumab injection as primary treatment. J Ocul Pharmacol Ther 2012; 28: 59-64.
Kim M, Lee P, Kim Y, Yu SY, Kwak HW. Effect of intravitreal Bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Ophthalmologica 2011; 226: 138-44.
Seo KH, Yu SY, Kim M, Kwak HW. Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns. Retina 2016; 36: 588-95.
Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmol 2011; 118: 609-14.
Yamamoto S, Yamamoto T, Hayashi M, Takeuchi S. Morphologic and functional analyses of diabetic macular edema by optical coherence tomography and multifocal electroretinograms. Graefes Arch ClinExp Ophthalmo 2001; 239: 96-101.
Kim BY, Smith SD, Kaiser PK. Optical coherence tomography patterns of diabetic macular edema. Am J Ophthalmol 2006; 142: 405-12.
Alkuraya H, Kangave D, Abu El-Asrar AM. The correlation between optical coherence tomographic features and severity of retinopathy, macular thickness and visual acuity in diabetic macular edema. Int Ophthalmol 2005; 26: 93-9.
Antonetti DA, Barber AJ, Khin S,Lieth E,Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occlusion content: vascular endothelial growth factor decreases occluding in retinal endothelial cells. Penn State Retina Research Group. Diabetes 1998; 47: 1953-9.
Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meet the eye. SurvOphthalmol2002; 47: S253-62.
Yanoff M, Fine BS, Brucker AJ, Eagle RC Jr. Pathology of human cystoid macular edema. Surv Ophthalmol 1984; 28: 505-11.
Fine BS, Brucker AJ. Macular edema and Cystoid macular edema. Am J Ophthalmol 1981; 92: 466-81.
Plate KH, Breier G, Weich HA, Rosau W. Vascular endothelial growth factor is the potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-8.
Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992: 359: 843-5.
Shimura M, Nakasawa T, Yazuda K, Shiono T, Iida T, Sakamoto T, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persist diffuse diabetic macular edema. Am J Ophthalmol 2008; 145: 854-61.
Ferris FL III, Patz A. Macular edema: a complication of diabetic retinopathy. Surv Ophthalmol 1984; 28: 452-61.
Kang SW, Park CY, Ham DI. The correlation between fluorescein angiographic and optical coherence tomographic features in clinical significant diabetic macular edema. Am J Ophthalmol 2004; 137: 313-22.